Iohexol is commonly used to help with diagnostic imaging procedures and is applied across domains where additional symptomatic support is needed. This agent is relevant in contexts involving heightened systemic burden and is used across domains where short-term symptom management is appropriate.

Iohexol is applied across domains where additional symptomatic support is needed and is indicated for use via numerous routes, including intravascular, intrathecal (spinal), oral, rectal, intraarticular (joints), and body cavity administration.

This agent assists in a variety of examinations. Iohexol is commonly used for managing symptoms that interfere with daily comfort in procedures such as angiography, myelography, CT enhancement of the head and body, urography, arthrography, and hysterography.

The overall goal is to provide supportive relief when symptoms interfere with routine activities. For example, during acute or unstable symptom patterns, it contributes to improved comfort by providing supportive relief when symptoms interfere with routine activities.

“This agent supports patients during episodes of heightened discomfort by is applied in addressing conditions presenting with systemic or localized discomfort and is relevant for easing symptoms characterized by periods of heightened symptoms.”

The use of iohexol may be part of symptomatic management and supports general well-being during symptomatic phases.

Quick Fact: Relief for symptoms related to physical discomfort

Eligibility Map: Who can and cannot use Iohexol TR

The eligibility profile for Iohexol (a radiographic contrast medium) is strictly defined by regulatory authorities and focuses on specific patient populations and conditions.

---

Populations for Whom Use is Contraindicated

Iohexol is contraindicated and must not be used by patients with a known hypersensitivity to iohexol or any excipient, or in those diagnosed with manifest thyrotoxicosis.

---

Eligibility and Restriction Rules

Category	Official Regulatory Statement
Age-Related	Intrathecal use is restricted to pediatric patients aged 2 weeks and older. Children aged 0 to 3 years require special thyroid function monitoring following exposure.
Condition-Specific	Use requires special caution and mandatory hydration in diabetic patients and the elderly with pre-existing renal impairment; preparatory dehydration is considered dangerous.
Specific Procedures	Use is contraindicated for the procedure of hysterosalpingography during pregnancy or suspected pregnancy. It is also prohibited for intrathecal use in the presence of a significant local or systemic infection.
Other Caution	Caution is advised for patients with severe cardiovascular disease, a history of epilepsy, chronic alcoholism, or multiple sclerosis (especially for intrathecal use).

The official regulatory profile for Iohexol details specific interaction patterns and mandatory timing rules. Co-administration of Corticosteroids is formally contraindicated when Iohexol is administered via the intrathecal route.

---

Administration Timing and Procedure Constraints

Several medications require specific timing adjustments relative to Iohexol injection. Metformin must be stopped at the time of or prior to the Iohexol procedure, and renal function must be reevaluated 48 hours after before resuming the medication. This risk concerning Metformin is heightened in patients with reduced kidney function, heart failure, hepatic impairment, or alcoholism. For myelography, drugs that lower the seizure threshold must be discontinued at least 48 hours prior to and 24 hours following the procedure.

---

Pharmacodynamic Interference

Iohexol may interfere with thyroid uptake of radioactive iodine, an effect that can persist for up to eight weeks, requiring a delay of protein-bound iodine tests for at least sixteen days. Additionally, Beta-blockers are documented to increase the severity of contrast reactions and reduce the effectiveness of emergency treatment with epinephrine. Iohexol also alters the plasma levels of specific diagnostic agents, including Iobenguane I 123 and Ioflupane I 123, by affecting their renal clearance.

Iohexol TR's action is entirely biophysical, focused on altering the way specific body compartments interact with X-ray energy, rather than modulating chemical pathways via receptors or enzymes.

X-Ray Photon Absorption and Radiopacity

The primary mechanism of Iohexol involves the high atomic density of its iodine atoms (Z=53) physically absorbing X-ray photons via the Photoelectric Effect. This molecular action creates concentration-dependent radiopacity, causing the fluid space the agent occupies to become instantly visible (bright white) on imaging. This is the core mechanistic cascade that results in the enhanced radiographic contrast which establishes the necessary radiographic contrast.

Mechanism of Confined Extracellular Distribution

The hydrophilic and nonionic structure of Iohexol is key to its distribution. It remains largely confined to the extracellular fluid compartment and the intravascular blood pool, as it is restricted from crossing cell membranes and the intact blood-brain barrier (BBB). This distribution mechanism ensures that the contrast is precisely focused on the fluid pathways and reveals a physiological state where the BBB integrity is compromised, resulting in the localization of contrast to specific anatomical structures. The effectiveness is intrinsically limited by physiological factors such as hemodilution and rapid renal filtration.

Physicochemical Effects

The solution's concentration creates a transient, localized increase in osmotic pressure, a physicochemical effect that can induce temporary, non-pharmacological vasodilation at the injection site.

How Iohexol TR is Used

Iohexol TR is a diagnostic contrast agent administered strictly for single-procedure medical imaging, following detailed protocols defined for medical use.

---

Administration Routes and Dosing

Administration is dictated by the specific body region being examined, with approved routes including Intrathecal, Intra-arterial, Intravenous, Oral, Rectal, Intraarticular, and various Body Cavity injections. The medicine must not be mixed with or administered in the same line as other medications.

Administration Type	Dosing Rule (Adults)	Notes on Use
Intrathecal (Spinal)	Total dose generally not to exceed 3,060 mg iodine.	Must be administered slowly (e.g., 1 to 2 minutes) and only with specific concentrations (180, 240, or 300 mgI/mL).
Intravenous (IV)	Dose is based on body weight ( mL/kg) or fixed volume per procedure (e.g., maximum cumulative dose of 250 mL for some procedures).	Administration should be at body or room temperature. Hydration is advised before and after the procedure.
Oral	Administered as a diluted solution (e.g., 6 to 12 mgI/mL final concentration).	Ingestion often occurs 20 to 60 minutes prior to image acquisition.

---

Procedural Requirements

Doses for pediatric patients are typically weight-based ( mL/kg), and specific concentration limits apply depending on the child's age and the route of administration. For oral use, Iohexol injection must be diluted with water, juice, or other suitable beverages just prior to use to achieve the required concentration for visualization. The medicine is intended for single-procedure use only, and any unused portion must be discarded.

Research evidence / Overview of Studies for Iohexol TR

---

Evidence for Visualization of Blood Vessels and Internal Organs

The evidence base for Iohexol's use in standard procedures like angiography (imaging blood vessels) and CT enhancement includes numerous Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined how effectively the agent provided diagnostic opacification, making internal structures visible. A key focus of this research was monitoring changes in renal function biomarkers (like serum creatinine) in the days immediately following the procedure. These findings describe patterns observed in the studies regarding short-term physiological responses when the agent was used in adult patients, including those with pre-existing kidney or heart issues.

Evidence for Diagnostic Imaging of the Spine and Brain

Research has explored the use of Iohexol administered directly into the spinal fluid (intrathecal administration) in diagnostic imaging procedures of the spinal cord (myelography). Comparative trials were evaluated to study diagnostic opacification and visualization quality, and to see how the agent was associated with physiological responses when compared to older contrast agents. The foundational research contributed to the evidence landscape for this specialized use, but that evidence provides limited modern comparative data.

Evidence for Imaging the Gastrointestinal Tract and Body Cavities

Iohexol was also evaluated in studies for its use when administered by mouth, rectally, or injected directly into joint spaces (arthrography). The research examined visualization quality and tracked how patients reported their experience regarding gastrointestinal tolerability. While evidence in pediatric populations was studied for these routes, the data supporting some of these specialized uses is limited compared to the large volume of data for intravascular use.

---

What is Still Uncertain About Iohexol TR Research

Clinical research is primarily focused on short-term physiological responses because the agent is rapidly cleared from the body. Consequently, long-term effects are not fully established regarding any physiological impact years after use. Furthermore, findings were mixed when trying to define a consistent difference in outcomes between Iohexol (a low-osmolality agent) and the newer iso-osmolar contrast agents. This means that comparative evidence is lacking for a definitive assessment of superiority across all patient types.

Key Studies & References WHO Model List of Essential Medicines (WHO-EML) entry for Iohexol

Common questions about Iohexol TR (FAQ)

---

Q: Can Iohexol TR be used while breastfeeding?

A: Limited data indicates Iohexol is excreted into human milk at low levels, as stated in official product information. Official guidance from the manufacturer may suggest a brief temporary interruption (such as 10 to 24 hours) to further limit infant exposure.

Q: What are the risks of using Iohexol TR for imaging the uterus and fallopian tubes?

A: Iohexol is indicated for the examination of the uterus and fallopian tubes (hysterosalpingography). However, the procedure is contraindicated (must not be performed) if pregnancy is suspected or confirmed. This restriction is due to the potential risks associated with the intrauterine procedure itself, as described in regulatory documents.

Q: Is it safe to receive Iohexol TR if I have a history of a reaction to a different contrast medium?

A: Official warnings state that caution is advised for people with a documented history of severe adverse reactions to any iodinated contrast media. Having this history is noted to potentially increase the risk of a reaction to Iohexol. This factor is typically considered during the pre-procedure assessment.

Q: Can Iohexol TR cause a headache right after the procedure?

A: Yes, headache is listed as a common and generally temporary adverse effect in the official product information. This effect is known to occur shortly after the administration of Iohexol.

Q: How long after receiving Iohexol TR do I need to wait before driving?

A: While regulatory documents do not specify a mandatory waiting period for driving, it is noted that Iohexol can cause side effects like dizziness, confusion, or visual disturbances. If you experience these effects, your ability to drive or operate machinery may be temporarily affected.

Q: Is it possible to have an allergic reaction to Iohexol TR even days after the scan?

A: The most serious, life-threatening allergic reactions typically occur within minutes of administration. However, official safety documentation indicates that other serious adverse skin reactions can have a delayed onset, occurring days later.

Q: Is having an allergy to shellfish a reason to avoid Iohexol TR?

A: No. Regulatory-cited guidelines indicate that an allergy to shellfish is not considered a contraindication for receiving Iohexol. This is due to the fact that shellfish allergies are linked to a specific protein, not the elemental iodine present in the contrast agent's molecule.

Q: Is a documented iodine allergy an absolute contraindication for using Iohexol TR?

A: Official documentation states that contraindications include a known severe hypersensitivity to Iohexol or any component of the drug, or a diagnosis of manifest thyrotoxicosis. Reactions are typically related to the agent's chemical structure rather than elemental iodine.

Q: What are the main health conditions that might make Iohexol TR riskier?

A: Regulatory warnings advise caution for individuals with pre-existing renal impairment, severe cardiovascular disease, a history of epilepsy, chronic alcoholism, or multiple sclerosis. Additionally, use is strictly prohibited in patients diagnosed with manifest thyrotoxicosis.

Q: How quickly does Iohexol TR work to show up on the scan?

A: According to the clinical pharmacology of the agent, peak blood levels occur immediately following rapid intravenous injection. Optimal visibility for imaging the renal passages, for example, typically occurs within 5 to 15 minutes after administration.

Q: How long does Iohexol TR stay in the body before it is fully cleared?

A: Iohexol is rapidly processed and eliminated from the body primarily by the kidneys. Official information states that approximately 90% or more of the injected dose is excreted within the first 24 hours.

Q: Why is the concentration of Iohexol TR sometimes diluted before use?

A: Dilution is a procedural requirement defined in the dosage instructions for specific uses. For oral administration, the injection solution must be diluted with water or another suitable beverage just prior to use. This is done to achieve the required low iodine concentration necessary for visualization during procedures like abdominal CT scans.

Q: What is the purpose of the salt-like ingredient (sodium calcium edetate) listed in the contrast agent?

A: Official regulatory documents list sodium calcium edetate as an excipient (an inactive ingredient) in the solution. In this formulation, this ingredient is understood to act as a stabilizing agent intended to help maintain the quality and integrity of the solution.

Q: Are there different strengths or concentrations of Iohexol TR available?

A: Yes, official dosage and administration documents indicate that Iohexol is manufactured in multiple concentrations. Common strengths include 180, 240, 300, and 350 mg of iodine per milliliter, with the specific strength used depending on the procedure and administration route.

Q: What is the difference between Iohexol TR and an ionic contrast agent?

A: Iohexol is classified as a non-ionic contrast agent, meaning its molecules remain uncharged in solution. Older ionic contrast agents dissociate into charged particles. The non-ionic structure is an advancement designed to enhance patient tolerance and potentially reduce the incidence of certain adverse effects.

Q: Can patients with sickle cell anemia use Iohexol TR safely?

A: Official warnings advise that caution is required when using Iohexol in patients with sickle cell anemia. This is because regulatory guidance indicates that the contrast medium may contribute to the worsening of the patient's condition.

Q: Is it safe to receive Iohexol TR if I have a history of hyperthyroidism or an overactive thyroid?

A: Official information advises caution for patients with hyperthyroidism (an overactive thyroid). Furthermore, the use of Iohexol is strictly contraindicated in patients who have manifest thyrotoxicosis, which is a severe form of hyperthyroidism.

Q: Why is there a caution for patients with pheochromocytoma regarding contrast agents?

A: Official warnings advise caution for patients with pheochromocytoma, a rare adrenal gland tumor. This is because the intravenous administration of contrast media may risk inducing a hypertensive crisis, which is a severe and sudden elevation in blood pressure.

Q: What are the differences in side effects between the oral Iohexol TR and the intravenous injection?

A: The official documentation lists general systemic adverse effects, like headache, that can occur with both routes. However, gastrointestinal effects, such as diarrhea, are specifically associated with the oral route of administration for the contrast agent.

Q: What happens if Iohexol TR leaks out of the vein during the injection (extravasation)?

A: Official guidance notes that extravasation (the leakage of the agent out of the vein) may potentially cause tissue damage. Because of this risk, it is advised that proper line placement is ensured and that the injection site is closely monitored during and after administration.

Q: How is Iohexol TR different from other contrast media used for imaging?

A: Iohexol is officially classified as a non-ionic, low osmolality iodinated contrast agent. This designation distinguishes it from older contrast agents due to its molecular stability and generally better physiological compatibility, as described in the product’s physicochemical properties.

Q: What is the difference between Iohexol TR and a gadolinium-based contrast agent?

A: Iohexol is an iodine-based contrast medium used for X-ray and CT imaging, functioning by physically absorbing X-rays. Gadolinium-based agents are chemically different, typically used for MRI (Magnetic Resonance Imaging) where they function by affecting magnetic field relaxation, making them suitable for different types of procedures.

Q: What is a non-ionic contrast medium and why is it used?

A: A non-ionic contrast medium, like Iohexol, does not separate into charged particles when dissolved in solution. This structural characteristic results in a low osmolality which is used to enhance patient tolerance and reduce the potential for adverse effects when compared to older agents.

Q: Will the doctor ask me to stay still or move in a specific way after I get the injection?

A: Official product information, particularly for intrathecal (spinal) use, notes that the agent must be administered slowly. In these cases, specific patient positions may be required to control the flow of the agent, implying a need for stillness or controlled movement during or immediately after the procedure.

Storage and Disposal Requirements for Iohexol

Iohexol (TR) must be stored strictly according to official regulatory guidelines to maintain its quality and efficacy. The medication must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to protect the product from light by storing it in its original packaging and to never freeze the solution. The solution should also not be warmed beyond body temperature (37 C) before use.

Once a single-dose container is opened, any unused portion must be discarded. Pharmacy Bulk Packages have a limited in-use stability period and must be used within eight hours after the container is entered. Before use, visually inspect the solution and do not administer if particulate matter or discoloration is present. Disposal of unused Iohexol must follow institutional or local regulatory requirements for waste, specifically avoiding bulk release into surface water or sewer systems.